- According to Transparency Market Research’s latest report on the global High Potency Active Pharmaceutical Ingredients (HPAPI) market for the historical period 2017–2018 and forecast period 2019–2027, growing preference for outsourcing of HPAPI manufacturing and rich pipeline with targeted therapeutic drugs are the factors likely to boost the growth of High Potency Active Pharmaceutical Ingredients (HPAPI) market. However, containment of technical expertise in the hands of few major players and lack of universal regulatory policies and standards is poised to escalate the growth of High Potency Active Pharmaceutical Ingredients (HPAPI) market.
- According to the report, the global High Potency Active Pharmaceutical Ingredients (HPAPI) market was valued at US$ 17.45 Bn in 2018 and is anticipated to expand at a CAGR of over 8.7% from 2019 to 2027
To know the scope of our report Get a Sample on High Potency Active Pharmaceutical Ingredient (HPAPI) Market
Growing preference for outsourcing of HPAPI manufacturing and rich pipeline with targeted therapeutic drugs: Key Drivers of Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market
- Pharmaceutical companies were skeptical in outsourcing manufacture of high potency APIs, and majority of the manufacturing was confined to captive or in-house. Major factor behind this was risk of patent infringement. However, as pharmaceutical companies started to expand geographical boundaries, they started experiencing shortage of HPAPIs. Furthermore, increasing cost of drug development and commercialization added to the financial burden. With developing regulatory and legal framework, outsourcing proved to be the most optimal option for HPAPI manufacturing.
- Pharmaceutical companies can now focus on core business activities such as drug development and commercialization, while also take advantage of technical expertise at CMOs instead of investing in expensive HPAPI manufacturing setup.
- Pharmaceutical companies have made significant investments in development of innovative drugs with targeted mode of action. Specific action and little or no side effects are major advantages for preference of such drugs. Various research articles published suggest that over 25% of the drugs in pipeline incorporate high potency active pharmaceutical ingredient (HPAPI). Currently only two antibody-drug conjugated drugs have been approved: Adcertis (Brentuximab vedotin) and Kadcyla (Trastuzumab emtansine). There are two other late stage candidates Inotuzumab ozogamicin (by, Pfizer) and IMMU-107 (by, Immunomedics). Several monoclonal antibody drugs are also expected to hit the market in the near future. Palivizumab, ofatumumab, KW-0761, and pembrolizumab are only a few examples of monoclonal antibody drugs in phase 3.
- With increasing number of potential phase 3 drug candidates, demand for contract manufacturing of HPAPIs has increased significantly in the recent past, and is one of the major drivers of the global HPAPI market.
Get a glimpse of the in-depth analysis through our Report Brochure
Patent Expiry of Blockbuster Drugs Propel Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Growth
- Patent expiry and subsequent launch of generic versions is a lucrative opportunity for pharmaceutical companies to expand product portfolio and tap profitable market segments in this technology driven market. Various biosimilar have been approved in Europe, while the U.S. FDA has approved only one biosimilar to date. Increase in research and development activities and constant attempts toward mimicking branded biological drugs would pave the way for introduction of cost-effective treatment alternatives.
- Various blockbuster drugs are expected to loose patent protection in the near future, providing large opportunities in the biosimilar market. Avastin (bevacizumab), Herceptin (trastuzumab), Synagis (palivizumab), Erbitux (cetuximab), Humira (adalimumab), Remicade (infliximab), and Rituxan (rituximab) are some of the major drugs going off patent in the near future.
Containment of Technical Expertise in the Hands of Few Major Players to Hamper Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market
- High potency API manufacturing is capital intensive and requires skilled technical know-how; this has been a major barrier for new entrants who wish to tap the lucrative HPAPI market. Currently, few major players exist who have built their own capabilities through mergers, acquisitions, partnerships, and research and development.
- Hence, the global HPAPI manufacturing market is leaning toward consolidation of expertise in the hands of few global players. Lonza, Novasep, SAFC, Cambrex, Teva API, Dr. Reddy’s Laboratories, and WuXi are key players in the HPAPI market.
Lack of Universal Regulatory Policies and Standards to Restrain Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market
- The high potency API market is a rapidly growing market with large numbers of players looking to invest in building capabilities for manufacturing of HPAPIs. HPAPIs are highly toxic to human body. Hence, high level of care is taken during manufacturing of these compounds. Despite these complications, there does not exist any specific occupational health, safety, and environmental protection regulations that cover manufacturing of HPAPIs.
- Private organizations such as Merck, Lonza, and SafeBridge have taken initiative to classify HPAPIs and (occupational exposure limits) OELs. However, CMOs need to maintain manufacturing standards as per client requirements due to lack of a universal guidelines. Introduction of universal guidelines and manufacturing policies would also provide credibility to CMOs, thus helping pharmaceutical companies in outsourcing business.
Expanding operations in future? To get the perfect launch ask for a custom report
Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market: Competitive Landscape
- This report profiles major players in the global High Potency Active Pharmaceutical Ingredients (HPAPI) market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
- The global High Potency Active Pharmaceutical Ingredients (HPAPI) market is highly fragmented, with the presence of a number of international as well as regional players
- Leading players operating in the global High Potency Active Pharmaceutical Ingredients (HPAPI) market are
- Alkermes plc
- Cambrex Corporation
- Dr. Reddy's Laboratories
- Lonza Group
- Novasep
- Novartis AG
- Pfizer
- Sigma-Aldrich Co. LLC.
- WuXi AppTec
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Teva Pharmaceutical Industries
- Eli Lilly and Company
- Abbvie.
Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market: Key Developments
Key players in the global High Potency Active Pharmaceutical Ingredients (HPAPI) market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global High Potency Active Pharmaceutical Ingredients (HPAPI) market. A few expansion strategies adopted by players operating in the global High Potency Active Pharmaceutical Ingredients (HPAPI) market are:
- In April 2019, U.S. based Cambrex Corporation expanded its new facility high-potency API production in U.S.
- In 2018, FDA approved 59 drugs, of that 42 were small molecules and 17 were biologics which accounts to about 28.8% of total approvals which has risen from 26.1% from the year 2017. Few biologic drugs approved in 2018 are Trogarzo, Ilumya, Crysvita, Aimovig, Poteligeo, Emgality, Libtayo and Takyzyro.
The report on the global High Potency Active Pharmaceutical Ingredients (HPAPI) market discussed individual strategies, followed by company profiles of manufacturers of High Potency Active Pharmaceutical Ingredients. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global High Potency Active Pharmaceutical Ingredients (HPAPI) market
Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market – Segmentation
|
API Type |
Synthetic Biological |
|
Manufacture Type |
Captive Contract |
|
Drug Type |
Branded Generic |
|
Therapeutic Application |
Oncology Drugs Anti-diabetic Drugs Cardiovascular Drugs Academic & Research Centers Pharmaceutical Companies Others |
|
Region |
North America Europe Asia Pacific Latin America Middle East & Africa |
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market
4. Market Overview
4.1. Introduction
4.1.1. Product Type/Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, 2017–2027
5. Key Insights
5.1. Value Chain Analysis
5.2. Event Impact analysis
5.3. Epidemiology of Cancer by Country/Sub-region
6. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, by API Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027
6.3.1. Synthetic
6.3.2. Biological
6.4. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness by Product Type
7. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, by Manufacture Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027
7.3.1. Captive
7.3.2. Contract
7.4. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness by Manufacture Type
8. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, by Drug Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027
8.3.1. Branded
8.3.2. Generic
8.4. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness by Drug Type
9. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, by Therapeutic Application
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027
9.3.1. Oncology Drugs
9.3.2. Anti-diabetic Drugs
9.3.3. Cardiovascular Drugs
9.3.4. CNS Drugs
9.3.5. Musculoskeletal Drugs
9.3.6. Other Drugs
9.4. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness by Therapeutic Application
10. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, by Region
10.1. Key Findings
10.2. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness by Country/Region
11. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027
11.2.1. Synthetic
11.2.2. Biological
11.3. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027
11.3.1. Captive
11.3.2. Contract
11.4. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027
11.4.1. Branded
11.4.2. Generic
11.5. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027
11.5.1. Oncology Drugs
11.5.2. Anti-diabetic Drugs
11.5.3. Cardiovascular Drugs
11.5.4. CNS Drugs
11.5.5. Musculoskeletal Drugs
11.5.6. Other Drugs
11.6. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Country, 2017–2027
11.6.1. U.S.
11.6.2. Canada
11.7. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis
11.7.1. By API Type
11.7.2. By Manufacture Type
11.7.3. By Drug Type
11.7.4. By Therapeutic Application
11.7.5. By Country
12. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027
12.2.1. Synthetic
12.2.2. Biological
12.3. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027
12.3.1. Captive
12.3.2. Contract
12.4. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027
12.4.1. Branded
12.4.2. Generic
12.5. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027
12.5.1. Oncology Drugs
12.5.2. Anti-diabetic Drugs
12.5.3. Cardiovascular Drugs
12.5.4. CNS Drugs
12.5.5. Musculoskeletal Drugs
12.5.6. Other Drugs
12.6. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Country, 2017–2027
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis
12.7.1. By API Type
12.7.2. By Manufacture Type
12.7.3. By Drug Type
12.7.4. By Therapeutic Application
12.7.5. By Country/Sub-region
13. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027
13.2.1. Synthetic
13.2.2. Biological
13.3. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027
13.3.1. Captive
13.3.2. Contract
13.4. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027
13.4.1. Branded
13.4.2. Generic
13.5. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027
13.5.1. Oncology Drugs
13.5.2. Anti-diabetic Drugs
13.5.3. Cardiovascular Drugs
13.5.4. CNS Drugs
13.5.5. Musculoskeletal Drugs
13.5.6. Other Drugs
13.6. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Country, 2017–2027
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis
13.7.1. By API Type
13.7.2. By Manufacture Type
13.7.3. By Drug Type
13.7.4. By Therapeutic Application
13.7.5. By Country/Sub-region
14. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027
14.2.1. Synthetic
14.2.2. Biological
14.3. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027
14.3.1. Captive
14.3.2. Contract
14.4. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027
14.4.1. Branded
14.4.2. Generic
14.5. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027
14.5.1. Oncology Drugs
14.5.2. Anti-diabetic Drugs
14.5.3. Cardiovascular Drugs
14.5.4. CNS Drugs
14.5.5. Musculoskeletal Drugs
14.5.6. Other Drugs
14.6. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Country, 2017–2027
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis
14.7.1. By API Type
14.7.2. By Manufacture Type
14.7.3. By Drug Type
14.7.4. By Therapeutic Application
14.7.5. By Country/Sub-region
15. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027
15.2.1. Synthetic
15.2.2. Biological
15.3. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027
15.3.1. Captive
15.3.2. Contract
15.4. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027
15.4.1. Branded
15.4.2. Generic
15.5. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027
15.5.1. Oncology Drugs
15.5.2. Anti-diabetic Drugs
15.5.3. Cardiovascular Drugs
15.5.4. CNS Drugs
15.5.5. Musculoskeletal Drugs
15.5.6. Other Drugs
15.6. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Country, 2017–2027
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis
15.7.1. By API Type
15.7.2. By Manufacture Type
15.7.3. By Drug Type
15.7.4. By Therapeutic Application
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of companies)
16.2. Market Share Analysis/Ranking By Company (2018)
16.3. Company Profiles
16.3.1. Alkermes plc,
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Growth Strategies
16.3.1.3. SWOT Analysis.
16.3.2. Cambrex Corporation
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Growth Strategies
16.3.2.3. SWOT Analysis.
16.3.3. Dr. Reddy's Laboratories
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Growth Strategies
16.3.3.3. SWOT Analysis.
16.3.4. Lonza Group
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Growth Strategies
16.3.4.3. SWOT Analysis.
16.3.5. Novasep
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Growth Strategies
16.3.5.3. SWOT Analysis.
16.3.6. Novartis AG
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Growth Strategies
16.3.6.3. SWOT Analysis.
16.3.7. Pfizer
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Growth Strategies
16.3.7.3. SWOT Analysis.
16.3.8. Sigma-Aldrich Co. LLC.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Growth Strategies
16.3.8.3. SWOT Analysis.
16.3.9. WuXi AppTec
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Growth Strategies
16.3.9.3. SWOT Analysis.
List of Table
Table 01: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027
Table 02: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027
Table 03: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 04: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027
Table 05: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 06: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 07: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027
Table 08: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027
Table 09: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 10: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027
Table 11: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2027
Table 12: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 13: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027
Table 14: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027
Table 15: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 16: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027
Table 17: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 18: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 19: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027
Table 20: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027
Table 21: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 22: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027
Table 23: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 24: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 25: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027
Table 26: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027
Table 27: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 28: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027
Table 29: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 30: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 31: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027
Table 32: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027
Table 33: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 34: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027
Table 35: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 36: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
List of Figure
Figure 01: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027
Figure 02: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, 2017–2027
Figure 03: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027
Figure 04: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), By Synthetic, 2017–2027
Figure 05: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), By Biological, 2017–2027
Figure 06: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027
Figure 07: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Manufacture Type, 2018 and 2027
Figure 08: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), By Captive, 2017–2027
Figure 09: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), By Contract, 2017–2027
Figure 10: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027
Figure 11: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027
Figure 12: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oncology Drugs, 2017–2027
Figure 13: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anti-diabetic Drugs, 2017–2027
Figure 14: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cardiovascular Drug, 2017–2027
Figure 15: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by CNS Drugs, 2017–2027
Figure 16: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Musculoskeletal Drugs, 2017–2027
Figure 17: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027
Figure 18: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027
Figure 19: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 20: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Branded, 2017–2027
Figure 21: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Generic, 2017–2027
Figure 22: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 23: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market, by Region, 2018 and 2027
Figure 24: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Region, 2019–2027
Figure 25: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 26: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027
Figure 27: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027
Figure 28: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027
Figure 29: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027
Figure 30: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027
Figure 31: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 32: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 33: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Country, 2018 and 2027
Figure 34: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Country, 2019–2027
Figure 35: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 36: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027
Figure 37: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027
Figure 38: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Manufacture Type, 2018 and 2027
Figure 39: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027
Figure 40: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027
Figure 41: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027
Figure 42: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 43: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 44: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 45: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 46: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 47: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027
Figure 48: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027
Figure 49: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Manufacture Type, 2018 and 2027
Figure 50: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027
Figure 51: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027
Figure 52: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027
Figure 53: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 54: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 55: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 56: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 57: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 58: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027
Figure 59: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027
Figure 60: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Manufacture Type, 2018 and 2027
Figure 61: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027
Figure 62: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027
Figure 63: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027
Figure 64: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 65: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 66: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 67: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 68: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 69: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027
Figure 70: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027
Figure 71: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Manufacture Type, 2018 and 2027
Figure 72: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027
Figure 73: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027
Figure 74: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027
Figure 75: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 76: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 77: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 78: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 79: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Share, by Company, 2018
